Diabetes Research and Clinical Practice - Volume 120 - Supplement 1

(20, 44), respectively. Prevalence of EDB atrophy in subjects

with Seiza habit was significantly higher than that in subjects

without Seiza habit (35 vs 20, p = 0.001). Therefore, female and

male were separately analyzed. In both gender, EDB atrophy

was significantly associated with ATR reduction and QVP

impairment.

Study II. EDB atrophy was observed in 49% of women and in

27% of men. In both gender, EDB atrophy was significantly

more prevalent in diabetic compared to non-diabetic subjects.

Inmale diabetic patients, all items of 8 quantitative nerve tests

were significantly associated with EDB atrophy. In female, only

4 items were associated with EDB atrophy. We evaluated the

predictive power of EDB atrophy for diagnosing the probable

DPN of Toronto consensus in diabetic men. The sensitivity,

specificity and positive predictive value of EB atrophy to

determine probable DPN were 48%, 92% and 83%, respectively.

Conclusion:

EDB atrophy was also seen in non-diabetic

subjects, but EDB atrophy was significantly associated with

peripheral neuropathy. EDB atrophy was more frequent in

female than male. The gender difference seemed to depend

the Seiza habit. In diabetic men, EDB atrophy clearly reflected

the DPN and EDB atrophy indicated the presence of DPN in

approximately 90% of probability.

OL03-4

Risks of progression to end-stage renal disease among type 2

diabetic patients with albuminuric and non-albuminuric

chronic kidney disease

Baoqi FAN

*, Andrea On Yan LUK

–

, Eric Siu Him LAU

Alice Pik Shan KONG

–

, Wing Yee SO

–

Ronald Ching Wan MA

–

, Risa OZAKI

1,2

Francis Chun Chung CHOW

1,2

, Juliana Chung Ngor CHAN

–

Department of Medicine and Therapeutics, The Chinese University of

Hong Kong,

Hong Kong Institute of Diabetes and Obesity,

Li Ka

Shing Institute of Health Sciences, Hong Kong

Diabetic kidney disease is heterogeneous in its clinical

manifestation. Many patients have declined glomerular filtra-

tion rate (GFR) without preceding albuminuria and they differ

in disease progression to those with albuminuric chronic

kidney disease (CKD). We examined clinical characteristics

and incidence of end-stage renal disease (ESRD) in a prospect-

ive cohort of Chinese patients with type 2 diabetes and CKD

stratified by albuminuria status.

Between 1 July 1994 and 31 December 2004, 1,995 of 10,129

patients who were enrolled into the Hong Kong Diabetes

Registry had CKD at baseline as defined by estimated GFR

<60 mL/min/1.73 m

. Albuminuria was confirmed based on

urine albumin-creatinine ratio >2.5 mg/mmol in men and

>3.5 mg/mmol in women. Patients were followed for new-

onset of ESRD as defined by estimated GFR <15 mL/min/

1.73 m

or dialysis.

Among 1,995 patients with CKD (mean ± standard deviation

[SD] age: 68.3 ± 10.1 years, median[interquartile range] disease

duration: 9[4, 15] years), 26.4% (n = 526) did not have albumin-

uria. Compared to patients with albuminuria (mean ± SD

estimated GFR: 41.7 ± 13.7 mL/min/1.73m

), those without

albuminuria (mean ± SD estimated GFR: 50.3 ± 9.1 mL/min/

1.73 m

) were older, had shorter disease duration, and had

lower blood glucose, blood pressure and cholesterol. The two

groups were similar in gender ratio, smoking status and

anthropometric indices. At baseline, patients without albu-

minuria were less likely to be complicated with diabetic

retinopathy and sensory neuropathy, but did not differ in

frequencies of coronary heart disease, stroke and congestive

heart failure relative to the albuminuric group, who had

greater prevalent use of renin-angiotensin system (RAS)

inhibitors and anti-hypertensive drugs.

Over a median follow-up period of 9.1 (interquartile range: 5.6,

12.6) years, 19.1% of non-albuminuric and 57.2% of albumi-

nuric patients without ESRD at baseline, developed ESRD.

Multivariate Cox regression was performed to estimate hazard

ratios (HRs) of non-albuminuric and albuminuric CKD strati-

fied by baseline use of RAS-inhibitors for incident renal events.

After adjustment for age, gender, disease duration, body mass

index, blood pressures, HbA1c and GFR, patients with albu-

minuriahad increasedhazardsof progressing toESRDwithHRs

3.23 (95% confidence interval [CI]: 2.42

–

4.30, p < 0.001) in those

using RAS-inhibitors and 2.70 (95% CI: 2.03

–

3.59, p < 0.001) in

thosenot using RAS-inhibitors, relative to reference groupof no

albuminuria and non-use of RAS-inhibitors at baseline.

In conclusion, patients with non-albuminuric CKD were less

likely to have other microvascular complications and had

lower risk of advancing to ESRD than patients with albumin-

uria, although rates of renal deterioration remained very high

in both groups.

OL03-5

High prevalence of cardio-renal complications among Chinese

subjects with Type 2 diabetes

–

The Hong Kong Diabetes

Biobank

Risa OZAKI

, Guozhi JIANG

, Fangying XIE

, Candice LAU

Pearl TSNAG

, Vince CHAN

, Cadmon LIM

, Andrea LUK

1,2

Chiu Chi TSANG

, Jenny LEUNG

, June LI

, Vincent YEUNG

Man Wo TSANG

, Grace KAM

, Ip Tim LAU

Chun Chung CHOW

, Ka Fai LEE

, Kam Piu LAU

Shing Chung SIU

, Juliana CHAN

1,2

, Wing Yee SO

1,2

Ronald MA

1,2

Department of Medicine and Therapeutics, The

Chinese University of Hong Kong,

Hong Kong Institute of Diabetes

and Obesity, The Chinese University of Hong Kong,

Diabetes and

Endocrine Centre, Alice Ho Miu Ling Nethersole Hospital,

Department of Integrated Medical Service, Ruttonjee Hospital,

Department of Medicine, Yan Chai Hospital,

Centre for Diabetes

Education and Management, Our Lady of Maryknoll Hospital,

Department of Medicine and Geriatrics, United Christian Hospital

Department of Medicine, Tseung Kwan O Hospital,

Department of

Medicine and Geriatrics, Kwong Wah Hospital,

Department of

Medicine, Northern District Hospital,

Diabetes Centre, Tung Wah

Hospital, Hong Kong

Aims:

Type 2 diabetes is associated with increased risk of

diabetic complications, in particular cardiovascular and renal

complications, which account for a significant proportion of

the healthcare burden associated with diabetes. There is

limited data on the epidemiology of diabetic complications

in a contemporary cohort. Our aim is to establish a territory-

wide registry and biobank of subjects with type 2 diabetes

(T2D), in order to study the epidemiology of diabetic complica-

tions and to utilize samples for biomarkers discovery and

replication.

Methods:

We recruited subjects at the time of regular

comprehensive diabetes complication screening at participat-

ing diabetes centres in major public hospitals in Hong Kong.

All subjects were consented for collection of clinical informa-

tion, baseline characteristics, biospecimens for archiving,

genetic and biomarker research and follow-up for develop-

ment of different diabetes-related outcomes. All specimens

were collected and processed through a standardized protocol.

Coronary heart disease is defined as history of myocardial

infarction or coronary revascularization procedures. Chronic

kidney disease is defined by eGFR <60 mL/min/1.73 m

by the

Chinese modified MDRD equation.

Results:

Recruitment commenced in March 2014. To date,

more than 7,700 subjects with type 2 diabetes have been

recruited, with more than 23,100 primary samples processed

and archived. Mean age of recruited subjects was 60.5 ± 10.8

years (male 58.6%), mean duration of diabetes 10 years. Mean

baseline HbA1c was 7.6 ± 1.4%. Retinopathy was present in

27.7% at recruitment and 34.1% were on insulin treatment. A

significant proportion have established chronic kidney disease

(defined as eGFR <60 mL/min/1.73 m

, 796 out of 6293, 12.6%)

and coronary heart disease (934 out of 6270, 14.9%). Subjects

Oral Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S40

–

S64

S46